Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

733 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
Dunn D, Price H, Vudriko T, Kityo C, Musoro G, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group. Dunn D, et al. Among authors: pillay d. J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):98-103. doi: 10.1097/QAI.0000000000002517. J Acquir Immune Defic Syndr. 2021. PMID: 33306565 Clinical Trial.
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Gibb DM, Walker AS, Kaye S, De Rossi A, Ait-Khaled M, Pillay D, Muñoz-Fernandez MA, Loveday C, Compagnucci A, Dunn DT, Babiker AG. Gibb DM, et al. Among authors: pillay d. Antivir Ther. 2002 Dec;7(4):293-303. Antivir Ther. 2002. PMID: 12553485 Clinical Trial.
Long-term persistence of primary genotypic resistance after HIV-1 seroconversion.
Pao D, Andrady U, Clarke J, Dean G, Drake S, Fisher M, Green T, Kumar S, Murphy M, Tang A, Taylor S, White D, Underhill G, Pillay D, Cane P. Pao D, et al. Among authors: pillay d. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1570-3. doi: 10.1097/00126334-200412150-00006. J Acquir Immune Defic Syndr. 2004. PMID: 15577410
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Phillips AN, et al. Among authors: pillay d. AIDS. 2005 Mar 25;19(5):487-94. doi: 10.1097/01.aids.0000162337.58557.3d. AIDS. 2005. PMID: 15764854
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.
Green H, Gibb DM, Compagnucci A, Giacomet V, de Rossi A, Harper L, Saïdi Y, Castelli-Gattinara G, Pillay D, Babiker AG, Aboulker JP, Lyall H, Bacheler LT, Walker AS, Debré M, Rosso R, Burger DM, Della Negra M, Dunn DT, Giaquinto C; Paediatric European Network for the Treatment of AIDS. Green H, et al. Among authors: pillay d. Antivir Ther. 2006;11(7):857-67. Antivir Ther. 2006. PMID: 17302248 Clinical Trial.
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.
Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A; UK Collaborative HIV Cohort Study. Phillips AN, et al. Among authors: pillay d. AIDS. 2007 Aug 20;21(13):1717-21. doi: 10.1097/QAD.0b013e32827038bf. AIDS. 2007. PMID: 17690569
733 results